Neurológia pre prax 5/2018

Hepatic impairment during the treatment multiple sclerosis by dimethyl-fumarate

Dimethyl-fumarate (DMF) is a drug indicated for relapsing-remitting forms of multiple sclerosis. Treatment leads to reduction of relapses, delays invalidity and supresses manifestations of disease shown on MRI. Treatment by DMF has also side effects, including gastrointestinal side effects and increase of liver enzymes activity. Clinical trials DEFINE and CONFIRM shown elevation of ALT in 6 % cases and discontinuation of treatment leaded do normalisation of liver tests. DMF is an effective and safe drug, possible increasing of liver tests does not mean serious risk, for which the treatment should by discontinued.

Keywords: multiple sclerosis, relapsing-remitting MS, dimethyl-fumarate, liver tests